Sertraline
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Sertraline: From Panic Disorder to Agoraphobia
One-Sentence Summary
Sertraline is a selective serotonin reuptake inhibitor (SSRI) with an established pharmacological role in panic disorder. Across eight candidate indications screened by the TxGNN model for this drug, Agoraphobia stands out as the only candidate reaching Level 1 evidence, supported by 4 clinical trials (including one completed Phase 4 RCT) and 19 publications, several of which are systematic reviews or network meta-analyses.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Panic disorder (per pharmacological rationale documented in this Evidence Pack; not independently confirmed via a South African licence record) |
| Predicted New Indication | Agoraphobia |
| TxGNN Prediction Score | 99.54% |
| Evidence Level | L1 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data for sertraline is not available in this Evidence Pack. Based on the pharmacological rationale associated with this candidate, sertraline is a selective serotonin reuptake inhibitor (SSRI) already established as effective in panic disorder — a condition that frequently co-occurs with, and shares core pathophysiology with, agoraphobia.
Panic disorder and agoraphobia sit on the same anxiety-disorder spectrum: agoraphobia commonly develops secondary to recurrent, unpredictable panic attacks, and the two are jointly assessed in DSM/ICD frameworks. Serotonergic modulation of anxiety-related limbic circuitry (amygdala–prefrontal pathways) provides a coherent pharmacological basis for extending sertraline’s panic-disorder efficacy to agoraphobia, rather than representing an unrelated mechanistic leap.
This is reflected in the clinical evidence itself: several of the RCTs and meta-analyses identified below explicitly evaluate “panic disorder with or without agoraphobia” as a combined study population, indicating that agoraphobia has already been treated as a related outcome measure in existing sertraline trials rather than as a wholly novel indication.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00677352 | Phase 4 | Completed | 321 | Randomised, double-blind, multicenter comparison of sertraline vs. paroxetine for panic disorder; direct active-comparator evidence. |
| NCT00182533 | Phase 4 | Terminated | 170 | Sertraline for generalized social phobia with psychiatric comorbidity; study halted before completion. |
| NCT05210153 | N/A | Unknown | 148 | Pharmacokinetic/CYP2C19 genotyping study for sertraline dose personalization; not an efficacy trial. |
| NCT05930912 | N/A | Unknown | 1 | Psychoanalytic treatment study in ASD with comorbid anxiety-spectrum conditions; minimal direct relevance (n=1). |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38014714 | 2023 | Network Meta-analysis | Cochrane Database Syst Rev | Network meta-analysis of pharmacological treatments for panic disorder, including agoraphobia-associated symptoms. |
| 35045991 | 2022 | Systematic Review/Network Meta-analysis | BMJ | Compares SSRIs for remission rates and adverse-event risk in panic disorder with or without agoraphobia. |
| 9734541 | 1998 | RCT | Am J Psychiatry | Double-blind multicenter trial establishing sertraline efficacy and safety in panic disorder. |
| 9819070 | 1998 | RCT | Arch Gen Psychiatry | Flexible-dose multicenter trial of sertraline in panic disorder. |
| 15096081 | 2004 | RCT | J Clin Psychiatry | Acute double-blind noninferiority comparison of sertraline vs. paroxetine in panic disorder. |
| 16053461 | 2005 | RCT | Bosnian J Basic Med Sci | Placebo-controlled comparison of sertraline and alprazolam, evaluating panic attacks and agoraphobia specifically. |
| 12191627 | 2002 | RCT sub-analysis | J Psychiatric Research | Early improvement predicts remission with sertraline in panic disorder (pooled fixed/flexible-dose studies, N=544). |
| 16505130 | 2006 | RCT | Am J Geriatric Psychiatry | CBT vs. sertraline for anxiety disorders in older adults. |
| 11110009 | 2000 | Pooled RCT analysis | Int Clin Psychopharmacol | Combined results of two fixed-dose sertraline studies in panic disorder with/without agoraphobia. |
| 37676054 | 2023 | Systematic Review | Expert Rev Neurother | Systematic review of pharmacological management of panic disorder in older patients. |
South Africa Market Information
Sertraline currently has no SAHPRA registrations recorded in this Evidence Pack (market status: Not Marketed). No product/registration details are available to tabulate.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Other Predicted Indications Screened
For context, seven additional candidate indications were generated by the same model run for sertraline; none reached comparable evidence strength:
| Rank | Disease | TxGNN Score | Evidence Level | Recommendation |
|---|---|---|---|---|
| 1 | Histrionic personality disorder | 99.93% | L5 | Hold |
| 2 | Paranoid personality disorder | 99.93% | L4 | Hold |
| 3 | Schizoid personality disorder | 99.93% | L5 | Hold |
| 4 | Schizotypal personality disorder | 99.93% | L4 | Research Question |
| 5 | Benign paroxysmal torticollis of infancy | 99.55% | L5 | Hold |
| 7 | Dependent personality disorder | 99.21% | L4 | Hold |
| 8 | Narcissistic personality disorder | 99.14% | L5 | Hold |
These candidates are largely driven by literature mismatches (e.g., unrelated case reports on lupus or binge-eating disorder) or comorbidity observations rather than direct treatment evidence, and are not recommended for further evaluation at this time.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Agoraphobia is supported by L1-level evidence — a completed Phase 4 RCT and multiple systematic reviews/network meta-analyses — largely because it is closely linked to sertraline’s established use in panic disorder. However, sertraline is not currently marketed in South Africa, and two blocking/high-severity data gaps (SAHPRA-equivalent PI warnings/contraindications, and confirmed mechanism of action) remain unresolved.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (warnings, contraindications) — currently a blocking data gap (DG001)
- Confirmed mechanism-of-action documentation from DrugBank or equivalent source (DG002)
- Confirmation of intended regulatory pathway, since sertraline has zero current SAHPRA registrations
- Drug-drug interaction data (DDI query returned no results) before any safety sign-off
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.